Text and Data Mining valid from 2019-06-12
Accepted: 8 May 2019
First Online: 12 June 2019
: B.B. has received compensation for consulting from Aduro, Alligator Biosciences, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DebioPharma, Genentech–Roche, Merck and TRM Oncology, has been a non-paid consultant of Adlai Norte and Celldex, has received compensation for serving on data safety monitoring committees for IDDI (AstraZeneca–Medimmune) and VentiRx, and for medical education activities from CCO, Chemo Advisor, PER, Peerview, Practice Update, Prime Oncology and OncLive, and has received travel support from Boehringer Ingelheim and Merck. Q.T.L. has received travel support for serving on the advisory board of Bristol-Myers Squibb, serves as a non-paid consultant of Merck, and serves on the data safety monitoring committee for a clinical trial sponsored by Pfizer. R.L.F. has received compensation for consulting and/or advisory board membership from AstraZeneca–Medimmune, Bristol-Myers Squibb, Merck, PER, Pfizer, Regeneron, Tesaro and TTMS Therapeutics. Through contracts with the UPMC Hillman Cancer Center, his laboratory has also been funded to perform sponsored research by AstraZeneca–Medimmune, Bristol-Myers Squibb and Tesaro. J.D.C. declares no competing interests.